The short version of growth hormone secretagogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-02 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
==== Aerobic ==== Aerobic exercise for fibromyalgia patients is the most investigated type of exercise. It includes activities such as walking, jogging, spinning, cycling, dancing and exercising in water, with walking being named as one of the best methods. A 2017 Cochrane summary concluded that aerobic exercise probably improves quality of life, slightly decreases pain and improves physical function and makes no difference in fatigue and stiffness. A 2019 meta-analysis showed that exercising aerobically can reduce autonomic dysfunction and increase heart rate variability. This happens when patients exercise at least twice a week, for 45–60 minutes at about 60%–80% of the maximum heart rate. Aerobic exercise also decreases anxiety and depression, and improves the quality of life. Exercising aerobically 2–3 times a week has been shown to alleviate pain.
A circuit of fluid in the loop of Henle—an important part of the kidneys—allows for gradual buildup of the concentration of urine in the kidneys, by using active transport on the exiting nephrons (tubules carrying liquid in the process of gradually concentrating the urea). The active transport pumps need only to overcome a constant and low gradient of concentration, because of the countercurrent multiplier mechanism. Various substances are passed from the liquid entering the nephrons until exiting the loop (See the nephron flow diagram). The sequence of flow is as follows:
Estimating the daily requirement for the indispensable amino acids has proven to be difficult; these numbers have undergone considerable revision over the last 20 years. The following table lists the recommended daily amounts currently in use for essential amino acids in adult humans (unless specified otherwise), together with their standard one-letter abbreviations.
Biko and several other black African NUSAS members were frustrated when it organised parties in white dormitories, which black Africans were forbidden to enter. In July 1967, a NUSAS conference was held at Rhodes University in Grahamstown; after the students arrived, they found that dormitory accommodation had been arranged for the white and Indian delegates but not the black Africans, who were told that they could sleep in a local church. Biko and other black African delegates walked out of the conference in anger. Biko later related that this event forced him to rethink his belief in the multi-racial approach to political activism:
On the other hand, the findings of animal studies of methenamine and carcinogenicity have also been questioned by some authors, though this topic is controversial. Antibiotics are known to disrupt the gut, urinary tract, and vaginal microbiota. This has been associated with increased risk of recurrent UTIs. Methenamine has been limitedly studied in this regard, but was found in one small study to preserve urinary microbial diversity. However, more studies are needed to assess the influence of methenamine on the host microbiome, both in the urinary tract and elsewhere in the body. Side effects of the topical form of methenamine for hyperhidrosis include dry skin, among others.
Sources: en.wikipedia.org
Moderate alcohol consumption, one standard drink per day, by breastfeeding mothers is not known to significantly affect infants; however, the American Academy of Pediatrics strongly discourages more than two standard drinks per day. Even one or two drinks, including beer, may reduce milk intake by 20 to 23%, leading to increased agitation and poor sleep patterns. Regular heavy drinking (more than two drinks daily) can shorten breastfeeding duration and cause issues in infants, such as excessive sedation, fluid retention, and hormonal imbalances. Additionally, higher alcohol consumption may negatively impact children's academic achievement. When breastfeeding, alcohol may be consumed in moderation and does not require "Pumping-and-Dumping" (pumping and discarding breastmilk). Alcohol crosses from the blood to the breastmilk by diffusion. Thus, the concentration of alcohol in the breastmilk is approximately equal to the concentration in the maternal bloodstream at any given time. As the mother's liver processes the alcohol, more and more alcohol is pulled out of the breastmilk and back into the bloodstream. Thus, it is suggested to wait 2 hours after drinking before nursing or pumping. In the case of infrequent binge drinking, it has been shown that infants consume through breastmilk only a fraction of the alcohol their mothers have ingested. While a minute, clinically insignificant amount of alcohol may be absorbed into the infant's bloodstream, it is unlikely that this amount would cause any noticeable cognitive or neuromotor effects.
=== Other === One common off-label use for topiramate is in the treatment of bipolar disorder. A review published in 2010 suggested a benefit of topiramate in the treatment of symptoms of borderline personality disorder; however, the authors noted that this was based on only one randomized controlled trial and requires replication. Topiramate has been used as a treatment for alcoholism. The U.S. Veterans Affairs and Department of Defense 2015 guideline on substance use disorders lists topiramate as a "strong for" in its recommendations for alcohol use disorder. Topiramate/phentermine combination therapy (trade name Qsymia) was approved by the USFDA in July 2012 for use by adults with obesity or overweight and a weight-related condition. Qsymia was approved by the USFDA in July 2022 for children and adolescents with age- and sex-standardized BMIs in or above the 95th percentile. Prior work had established single-agent topiramate therapy as weight loss-inducing in select populations (e.g., those with binge eating disorder or atypical antipsychotic-induced weight gain).
After military leaders are assassinated, Gunnery Sergeant Brandon Beckett receives word that his father is one. Attempting to track down the assassin, Brandon finds out that his father is not dead, realizing that he is being used as bait.
Injury causes multiple effects at different biological levels from molecular and cellular to physiological, organismal, behavioural, and ecological. These include such harmful effects as direct damage to cells and tissues; loss of energy reserves; stress responses and changes to immune function; defensive behaviour; and reduced ability to move, feed, reproduce, and compete. In addition, injury sets off a chain of responses that tend to restore structure and function.
=== Pharmacodynamics === 3-MeO-PCP has a Ki of 20 nM for the PCP site of the NMDA receptor, which is higher than PCP or any other anisyl substition of PCP. It has secondary activity at multiple other receptors, with a Ki of 216 nM for the serotonin transporter (SERT), and 42 nM for the sigma σ1 receptor. It does not bind to the norepinephrine or dopamine transporter, nor to the sigma σ2 receptor (Ki >10,000 nM). Based on structural similarity to 3-HO-PCP, it was initially expected that 3-MeO-PCP may have opioid activity. However, radioligand binding assays confirmed that the drug lacks significant activity at μ-, δ-, or κ-opioid receptors.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.